July’s top stories: Samsung’s new full-body CT scanner, Cardinal’s $6.1bn deal with Medtronic
Samsung NeuroLogica launched a new mobile, portable full-body computed tomography (CT) scanner, BodyTom Elite, and Cardinal Health concluded the purchase of Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business from Medtronic for $6.1bn. Medicaldevice-network.com wraps-up the key headlines from July, 2017.
Samsung Electronics’ healthcare unit Samsung NeuroLogica launched a new mobile, portable full-body computed tomography (CT) scanner, BodyTom Elite.
The new CT system is an upgraded version of the firm’s BodyTom 32-slice CT scanner and features new visual design, upgraded software, hardware, and workstation.
Hardware upgrades to the scanner include linear and step calibration, tilt sensor, step correction, and a quieter lift and translate system. The workstation improvements include battery backup, two-way patient communication system, and better processing speed and export options.
Cardinal Health concluded the purchase of Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business from Medtronic for a total of $6.1bn.
The transaction was funded with new senior unsecured notes of $4.5bn, existing cash and borrowings under Cardinal’s current credit arrangements.
Initiated in April, the deal was subjected to regulatory approvals and other customary closing conditions.
Researchers at the Purdue University in the US developed a new MRI-compatible, wireless recording device to bridge neuro-technologies for diagnostics and enhance the safety of patients.
The technology is developed by Purdue College of Engineering graduate research assistants Ranajay Mandal and Nishant Babaria under the guidance of Weldon School of Biomedical Engineering and the School of Electrical and Computer Engineering assistant professor Zhongming Liu.
When placed in existing MRI machines, the small self-learning device allows simultaneous medical imaging and recording, enabling effective and safe patient monitoring.
US-based diagnostic solutions provider Quidel signed definitive agreements to buy Triage assets from point-of-care (POC) diagnostics firm Alere for around $400m and an additional $40m in contingent consideration.
The agreement includes the Triage MeterPro cardiovascular (CV) and toxicology assets, real estate for the Triage facilities at San Diego, US, and the B-type Naturietic Peptide (BNP) assay business.
The deal is expected to diversify Quidel’s overall business and bolster its presence in the POC market, while the combination of businesses will offer rapid diagnostics in critical care settings.
Medtronic’s Canadian subsidiary launched its new magnetic resonance imaging (MRI) conditional cardiac resynchronisation therapy defibrillators (CRT-Ds) in Canada after receiving Health Canada licence.
Designed to address heart failure, the Medtronic Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan devices can now be used for MRI scans on all body parts and do not have any positioning restrictions.
The new systems feature quadripolar technology to optimise CRT delivery for improved outcomes and to provide various options for heart failure patients.
Researchers at Washington University School of Medicine in St Louis, US, carried out a study to identify a rapid and inexpensive test for Alzheimer’s disease.
The results from the study suggested that screening of amyloid beta protein, which is a characteristic of Alzheimer’s, in the blood can help identify individuals with altered amyloid levels in the brain or cerebrospinal fluid.
It is expected that the blood-based screening test will have the potential for early detection of the disease, even years before their symptoms-based diagnosis.
The University of Birmingham in the UK secured £7m funding from the National Institute for Health Research (NIHR) to launch a joint research unit with the Universities of Edinburgh and Warwick to develop global surgical research.
To be based at the University of Birmingham, the new NIHR Global Health Research Unit on Global Surgery will be led by the university’s Institute of Cancer and Genomic Sciences colorectal surgeon professor Dion Morton and the Birmingham Clinical Trials Unit director professor Peter Brocklehurst.
The unit is set to establish sustainable international research hubs in low and middle-income countries (LMICs) over four years, until March 2021.
Abbott signed an agreement to integrate its FreeStyle Libre glucose sensing technology with Bigfoot Biomedical’s insulin delivery solutions to develop and commercialise diabetes management systems in the US.
Under the agreement, Bigfoot will use the glucose sensing technology to develop personalised, user-friendly systems for optimised insulin delivery and better diabetes management.
The firm will additionally develop systems for auto-titration of its connected insulin injection devices and for automated delivery with its insulin infusion platform.
GE and Global Good Fund entered a licensing deal with diagnostics technology developer Access Bio for the manufacture and distribution of new rapid diagnostic tests (RDTs) to detect asymptomatic malaria in low-resource regions.
Co-developed by GE Global Research Centre and Global Good, the new malaria diagnostic technologies are expected to aid in the global elimination of the disease.
Formed as a result of an alliance between Intellectual Ventures and Bill Gates, Global Good focuses on the invention of technology to improve the quality of life in low and middle-income countries.
Royal Philips entered an agreement with the Singapore Institute of Advanced Medicine Holdings (SAM) to build a new oncology centre in the country.
To be built in collaboration with Varian Medical Systems and IBA Worldwide, and based at the country’s biomedical research hub Biopolis, the new Advanced Medicine Oncology Centre will offer imaging, treatment delivery and clinical informatics technologies.
SAM is set to invest approximately S$100m ($72m) for the development of the research, training and treatment centre that is scheduled to open in stages from next year.